Aytu BioPharma Inc. (NASDAQ:AYTU) Receives Consensus Rating of “Hold” from Analysts

Aytu BioPharma Inc. (NASDAQ:AYTU) has been given an average recommendation of “Hold” by the five research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $9.8333.

Several research firms recently issued reports on AYTU. Weiss Ratings reissued a “sell (d-)” rating on shares of Aytu BioPharma in a report on Wednesday, April 8th. Ascendiant Capital Markets increased their price target on shares of Aytu BioPharma from $14.00 to $14.50 and gave the stock a “buy” rating in a report on Thursday, June 11th. Finally, Zacks Research raised shares of Aytu BioPharma from a “strong sell” rating to a “hold” rating in a report on Monday, May 11th.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP increased its holdings in Aytu BioPharma by 23.3% in the first quarter. Dimensional Fund Advisors LP now owns 43,585 shares of the company’s stock valued at $119,000 after buying an additional 8,222 shares in the last quarter. Daytona Street Capital LLC purchased a new position in Aytu BioPharma in the fourth quarter valued at about $26,000. Persistent Asset Partners Ltd increased its holdings in Aytu BioPharma by 27.2% in the fourth quarter. Persistent Asset Partners Ltd now owns 79,415 shares of the company’s stock valued at $206,000 after buying an additional 16,963 shares in the last quarter. Rothschild Wealth LLC purchased a new position in Aytu BioPharma in the fourth quarter valued at about $52,000. Finally, Bellevue Asset Management LLC purchased a new position in Aytu BioPharma in the fourth quarter valued at about $65,000. 33.49% of the stock is owned by hedge funds and other institutional investors.

Aytu BioPharma Stock Performance

NASDAQ AYTU opened at $2.31 on Friday. The stock has a market capitalization of $24.79 million, a P/E ratio of -0.50 and a beta of 0.24. Aytu BioPharma has a 52-week low of $1.65 and a 52-week high of $3.07. The firm has a 50-day moving average price of $2.34 and a 200 day moving average price of $2.46. The company has a quick ratio of 1.00, a current ratio of 1.12 and a debt-to-equity ratio of 0.27.

Aytu BioPharma (NASDAQ:AYTU) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.09). The firm had revenue of $12.41 million for the quarter, compared to analysts’ expectations of $12.05 million. Aytu BioPharma had a negative return on equity of 69.93% and a negative net margin of 60.17%. Equities research analysts expect that Aytu BioPharma will post -0.73 EPS for the current year.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.